Jeanne Living Morrow

US Patent:

20050281830, Dec 22, 2005

Filed:

Jan 24, 2005

Appl. No.:

11/041471

Inventors:

Phillip Morrow - San Diego CA, US
Jeanne Morrow - San Diego CA, US
Angray Kang - Encinitas CA, US
Fei Wang - San Diego CA, US
Ivy Jiang - San Diego CA, US
Ritsuko Sawada - San Diego CA, US
Wolfgang Scholz - San Diego CA, US

International Classification:

G01N033/554
G01N033/569
A61K039/40

US Classification:

424164100, 435007320

Abstract:

A highly efficient method for generating human antibodies using recall technology is provided. In one aspect, human antibodies which are specific to the anthrax toxin are provided. In one aspect, human peripheral blood cells that have been pre-exposed to anthrax toxin are used in the SCID mouse model. This method results in high human antibody titers which are primarily of the IgG isotype and which contain antibodies of high specificity and affinity to desired antigens. The antibodies generated by this method can be used therapeutically and prophylactically for preventing or treating mammals exposed to anthrax. Thus, in one embodiment, a prophylactic or therapeutic agent used to counter the effects of anthrax toxin, released as a mechanism of bioterrorism, is provided. In one embodiment, a formulation and method for preventing and/or treating anthrax infection comprising a binding agent that prevents the assembly of the PA63 heptamer is also provided. Methods for diagnosis and methods to determine anthrax contamination are also described.

US Patent:

20060246079, Nov 2, 2006

Filed:

Jan 21, 2005

Appl. No.:

11/040580

Inventors:

Phillip Morrow - San Diego CA, US
Jeanne Morrow - San Diego CA, US
Angray Kang - Encinitas CA, US
Fei Wang - San Diego CA, US
Ivy Jiang - San Diego CA, US
Ritsuko Sawada - San Diego CA, US
Wolfgang Scholz - San Diego CA, US

International Classification:

A61K 39/40
C07K 16/12

US Classification:

424164100, 530388400

Abstract:

A highly efficient method for generating human antibodies using recall technology is provided. In one aspect, human antibodies which are specific to the anthrax toxin are provided. In one aspect, human peripheral blood cells that have been pre-exposed to anthrax toxin are used in the SCID mouse model. This method results in high human antibody titers which are primarily of the IgG isotype and which contain antibodies of high specificity and affinity to desired antigens. The antibodies generated by this method can be used therapeutically and prophylactically for preventing or treating mammals exposed to anthrax. Thus, in one embodiment, a prophylactic or therapeutic agent used to counter the effects of anthrax toxin, released as a mechanism of bioterrorism, is provided. In one embodiment, a formulation and method for preventing and/or treating anthrax infection comprising a binding agent that prevents the assembly of the PA63 heptamer is also provided. Methods for diagnosis and methods to determine anthrax contamination are also described.

US Patent:

20080063647, Mar 13, 2008

Filed:

Jan 24, 2005

Appl. No.:

11/041318

Inventors:

Phillip R. Morrow - San Diego CA, US
Angray S. Kang - Encinitas CA, US
Fei Wang - San Diego CA, US
Ivy Jiang - San Diego CA, US
Ritsuko Sawada - San Diego CA, US
Wolfgang Scholz - San Diego CA, US
Jeanne Morrow - San Diego CA, US

International Classification:

A61K 39/40
C07K 16/12

US Classification:

4241641, 5303884

Abstract:

A highly efficient method for generating human antibodies using recall technology is provided. In one aspect, human antibodies which are specific to the anthrax toxin are provided. In one aspect, human peripheral blood cells that have been pre-exposed to anthrax toxin are used in the SCID mouse model. This method results in high human antibody titers which are primarily of the IgG isotype and which contain antibodies of high specificity and affinity to desired antigens. The antibodies generated by this method can be used therapeutically and prophylactically for preventing or treating mammals exposed to anthrax. Thus, in one embodiment, a prophylactic or therapeutic agent used to counter the effects of anthrax toxin, released as a mechanism of bioterrorism, is provided. In one embodiment, a formulation and method for preventing and/or treating anthrax infection comprising a binding agent that prevents the assembly of the PA heptamer is also provided. Methods for diagnosis and methods to determine anthrax contamination are also described.

US Patent:

20080081042, Apr 3, 2008

Filed:

Jan 24, 2005

Appl. No.:

11/041763

Inventors:

Phillip R. Morrow - San Diego CA, US
Angray S. Kang - Encinitas CA, US
Fei Wang - San Diego CA, US
Ivy Jiang - San Diego CA, US
Ritsuko Sawada - San Diego CA, US
Wolfgang Scholz - San Diego CA, US
Jeanne Morrow - San Diego CA, US

International Classification:

A61K 39/40
C07K 16/12

US Classification:

4241641, 5303884

Abstract:

A highly efficient method for generating human antibodies using recall technology is provided. In one aspect, human antibodies which are specific to the anthrax toxin are provided. In one aspect, human peripheral blood cells that have been pre-exposed to anthrax toxin are used in the SCID mouse model. This method results in high human antibody titers which are primarily of the IgG isotype and which contain antibodies of high specificity and affinity to desired antigens. The antibodies generated by this method can be used therapeutically and prophylactically for preventing or treating mammals exposed to anthrax. Thus, in one embodiment, a prophylactic or therapeutic agent used to counter the effects of anthrax toxin, released as a mechanism of bioterrorism, is provided. In one embodiment, a formulation and method for preventing and/or treating anthrax infection comprising a binding agent that prevents the assembly of the PA63 heptamer is also provided. Methods for diagnosis and methods to determine anthrax contamination are also described.

US Patent:

20090202553, Aug 13, 2009

Filed:

Aug 29, 2008

Appl. No.:

12/230549

Inventors:

Phillip R. Morrow - San Diego CA, US
Angray S. Kang - Encinitas CA, US
Fei Wang - San Diego CA, US
Ivy Jiang - San Diego CA, US
Ritsuko Sawada - San Diego CA, US
Wolfgang Scholz - San Diego CA, US
Jeanne Morrow - San Diego CA, US

Assignee:

Emergent Product Development Gaithersburg Inc. - Gaithersburg MD

International Classification:

C07K 16/12
C12N 15/13
C12N 15/85
C12N 5/10
C12P 21/08
A61K 39/40
A61P 31/04

US Classification:

4241391, 5303879, 536 2353, 4353201, 435340, 435 696

Abstract:

A highly efficient method for generating human antibodies using recall technology is provided. In one aspect, human antibodies which are specific to the anthrax toxin are provided. In one aspect, human peripheral blood cells that have been pre-exposed to anthrax toxin are used in the SCID mouse model. This method results in high human antibody titers which are primarily of the IgG isotype and which contain antibodies of high specificity and affinity to desired antigens. The antibodies generated by this method can be used therapeutically and prophylactically for preventing or treating mammals exposed to anthrax. Thus, in one embodiment, a prophylactic or therapeutic agent used to counter the effects of anthrax toxin, released as a mechanism of bioterrorism, is provided. In one embodiment, a formulation and method for preventing and/or treating anthrax infection comprising a binding agent that prevents the assembly of the PA63 heptamer is also provided. Methods for diagnosis and methods to determine anthrax contamination are also described.